MissionIR Articles
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Roundtable
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the Virtual Investor Roundtable Event,…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Berubicin’s Impressive Potential in Syndicated Broadcast
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that it has been featured in…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Group of Patients in Potentially Pivotal Trial
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced the dosing of the first patients…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2021 Financial Results, Provides Business Outlook
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the quarter…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Clear Opportunity to Bring Impactful Therapy to GBM Patients
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Looking to Unlock Additional Value with Russell 2000 Index Inclusion
CNS Pharmaceuticals (NASDAQ: CNSP), a pharmaceutical company enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of its lead drug candidate, was selected to…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Begin Patient Dosing in Berubicin Phase 2 Clinical Trial During Q3 2021, and Received Fast Track Designation from FDA
CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatments Enrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Fast Track Designation for Lead Investigational Drug
CNS Pharmaceuticals’ (NASDAQ: CNSP) lead investigational drug, Berubicin, has been granted fast track designation by the U.S. Food and Drug Administration (“FDA”). That announcement came from WPD Pharmaceuticals Inc.(CSE: WBIO) (FSE: 8SV1), a clinical-stage pharmaceutical company that…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin’s Development
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Among the highlights, the…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives FDA Fast Track Status for Berubicin Study
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), WPD Pharmaceuticals to Soon Recruit Patients for Combined Berubicin Clinical Studies
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, sublicenses the compound Berubicin to WPD Pharmaceuticals for 30…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Committed to Driving Novel Treatments Forward with Key Focus on Berubicin
CNS Pharmaceuticals’ (NASDAQ: CNSP) lead drug candidate, Berubicin, is a novel anthracycline, the first of which to appear capable of crossing the blood-brain barrier based on limited clinical data. The company is currently developing Berubicin…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gains Inclusion on Russell 2000 Index as Brain Cancer Trial Enrollment Advances
Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition CNS’s focus has…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reports First Quarter Financials; Anticipates Improved Patient Outcomes with Berubicin
Company expects reporting on interim analysis for the first 18 patients of a Phase 2 multicenter clinical trial of Berubicin in adult GBM patients during the first half of 2022 One patient from the first…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Set for Inclusion in Russell 2000 Index
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the company will be added to the…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Nears Dosing of Phase 2 Patients with Standout Anthracycline Therapy
CNS Pharmaceuticals (NASDAQ: CNSP) is focused on producing a treatment that improves on the effectiveness of established chemotherapy drug lomustine in increasing overall survival rates of glioblastoma multiforme (“GBM”) patients. GBM is an illness that…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Study Promising Candidate in Phase 2 GBM Trial
CNS Pharmaceuticals (NASDAQ: CNSP) is on track to begin a potentially pivotal Phase 2 trial during the second quarter of 2021. This trial of CNSP’s lead drug candidate, Berubicin, in the treatment of glioblastoma multiforme…
-
GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial
Biopharmaceutical developer CNS Pharmaceuticals is working on ways to improve overall survivability for glioblastoma multiforme (“GBM”) brain cancer patients GBM is considered to be an incurable brain cancer that usually only leaves patients about 15…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Patient Enrollment in Berubicin Study
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has begun open enrollment for its upcoming study focused…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2021 Results, Provides Clinical Update and Business Outlook
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided a clinical update and business outlook and…
Search Articles
Latest Articles
- A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Advancing Retail Innovation Through AI-Powered Smart-Cart Technology
- Forward Industries Inc. (NASDAQ: FWDI) Positive Update for Shareholders After Debuting the Company’s Solana Treasury Strategy
- Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures Funding to Strengthen North American Supply Chain
- MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast